During the past decade, Hopital Haut-Leveque conducted 309 clinical trials. In the 10-year time frame, 309 clinical trials started and 102 clinical trials were completed, i.e. on average, 33% percent of trials that started reached the finish line to date. In the past 5 years, 142 clinical trials started and 63 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital Haut-Leveque" #1 sponsor was "University Hospital, Bordeaux" with 29 trials, followed by "Celgene" with 25 trials sponsored, "Groupe Francophone des Myelodysplasies" with 15 trials sponsored, "Gilead Sciences" with 14 trials sponsored and "Janssen Research & Development, LLC" with 14 trials sponsored. Other sponsors include 403 different institutions and companies that sponsored additional 180 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital Haut-Leveque" #1 collaborator was "Novartis" with 7 trials as a collaborator, "AbbVie" with 5 trials as a collaborator, "Celgene" with 5 trials as a collaborator, "Celgene Corporation" with 5 trials as a collaborator and "Ministry of Health, France" with 5 trials as a collaborator. Other collaborators include 181 different institutions and companies that were collaborators in the rest 144 trials.

According to Clinical.Site data, the most researched conditions in "Hopital Haut-Leveque" are "Multiple Myeloma" (23 trials), "Ulcerative Colitis" (16 trials), "Acute Myeloid Leukemia" (13 trials), "Myelodysplastic Syndromes" (12 trials) and "Atrial Fibrillation" (11 trials). Many other conditions were trialed in "Hopital Haut-Leveque" in a lesser frequency.

Most popular intervention types in "Hopital Haut-Leveque" are "Drug" (346 trials), "Device" (72 trials), "Other" (50 trials), "Procedure" (30 trials) and "Biological" (28 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (66 trials), "Lenalidomide" (16 trials), "Dexamethasone" (13 trials), "Rituximab" (12 trials) and "Azacitidine" (11 trials). Other intervention names were less common.

The vast majority of trials in "Hopital Haut-Leveque" are 501 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are 195 active trials in "Hopital Haut-Leveque". 5 are not yet recruiting, 111 are recruiting, 77 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 235 completed trials in Hopital Haut-Leveque, 1 suspended trials, and 41 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital Haut-Leveque, 38 "Phase 1" clinical trials were conducted, 151 "Phase 2" clinical trials and 174 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 22 trials, and there were also 74 trials that are defined as “Not Applicable".